The main challenge of CML therapy is acquired resistance to IM, a first-line drug for CML treatment, caused by additional mutations in the BCR/ABL fusion gene, resulting in failure of treatment and relapse26. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.